SCHEMBL3763675

SCHEMBL3763675

CCN(CC)CCN(C)C(=O)Cc1ccn[c]c1-c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 5/20 0.37
ACHE P22303 5/20 0.37
LTB4R Q15722 4/20 0.36
LTB4R2 Q9NPC1 4/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
SCN1A P35498 2/20 0.35
SCN2A Q99250 2/20 0.35
SCN3A Q9NY46 2/20 0.35
MCHR1 Q99705 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
AGTR1 P30556 1/20 0.35
TRPM8 Q7Z2W7 1/20 0.34
HTR1A P08908 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758958 0.74 SMN1; SMN2 (0.33) ALDH1A1MAPTHTR1AHRH3L3MBTL1
SCHEMBL3769349 0.72 TRPM8 (0.47) ALDH1A1MAPTTRPM8
SCHEMBL3754700 0.69 HTR2C (0.41) ALDH1A1L3MBTL1
SCHEMBL3763681 0.69 KMT2A (0.42) ADORA2AADORA1KDM4EALDH1A1TRPM8
SCHEMBL3763076 0.68 PDCD1 (0.38) KDM4EALDH1A1MAPTCYP1A2
SCHEMBL3759361 0.68 ACHE (0.40) BCHEACHELTB4RLTB4R2MCHR1
SCHEMBL3764668 0.68 HPGD (0.49) ALDH1A1MAPTMAPK1
SCHEMBL3769363 0.66 MAPT (0.32) MAPTMAPK1
SCHEMBL3758759 0.66 KMT2A (0.50) KDM4EALDH1A1TRPM8MAPK1CYP2D6
SCHEMBL3759364 0.66 BCHE (0.39) BCHEACHELTB4RLTB4R2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA BCHE 2335/4885ACHE 848/4885LTB4R 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.